Health Canada Approves Ozempic to Protect Kidneys in People with Type 2 Diabetes
Health Canada has approved Ozempic (semaglutide) for a new use: reducing the risk of kidney deterioration in patients with Type 2 diabetes and chronic kidney disease.
This approval is based on results from the international FLOW trial, which showed that people taking Ozempic had a 24% lower risk of kidney failure, dialysis, or major kidney decline compared to those receiving a placebo.
